Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
crizotinib + lorlatinib
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Crizotinib + lorlatinib is a combination of two small molecule tyrosine kinase inhibitors used in the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Crizotinib inhibits ALK, ROS1, and MET kinases, while lorlatinib is a third-generation inhibitor targeting ALK and ROS1 with enhanced central nervous system penetration. This combination has been explored in clinical trials for patients with resistance to prior ALK inhibitors. The rationale for combining or alternating these drugs includes suppressing or delaying the emergence of drug-resistant tumor clones by targeting different resistance pathways, such as MET dysregulation that can arise during lorlatinib therapy[1][3][4]. Both drugs are developed and manufactured by Pfizer.
- Brand names
- Xalkori (crizotinib)Lorbrena (lorlatinib)
- Other names
- crizotinib and lorlatinib combination
02
Targets
ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)
Beyond the preview
Go deeper on crizotinib + lorlatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on crizotinib + lorlatinib.